Seeking Alpha

Nordion Inc. (NDZ)

NDZ is defunct.
  • Jun. 2, 2014, 11:53 AM
    • Nordion Inc. (NDZ): FQ2 EPS of $0.22 misses by $0.04.
    • Revenue of $74.7M (+33.2% Y/Y) beats by $9.45M.
    • Shares +7.7%.
    • Press Release
    | Comment!
  • Mar. 7, 2014, 7:07 AM
    • Nordion (NDZ): FQ1 EPS of $0.59 beats by $0.37.
    • Revenue of $70.8M (+32% Y/Y) beats by $4.25M.
    • Press Release
    | 1 Comment
  • Jan. 9, 2014, 7:03 AM
    • Nordion (NDZ): FQ4 EPS of $0.15 misses by $0.03.
    • Revenue of $51.3M (-31% Y/Y) misses by $0.39M. (PR)
    | Comment!
  • Sep. 5, 2013, 12:25 PM
    • Nordion (NDZ +1.8%) gains after posting a solid FQ4 earnings beat this morning.
    • Net profit surged, thanks to the sale of one of its business units. In July the company sold its targeted-therapies unit to BTG PLC for $190M, resulting in a gain of about $182M.
    • Total revenue grew by 6.8% Y/Y, while gross margin was flat at 55%.
    • Medical-isotopes segment sales +9% Y/Y.
    • Sterilization-technologies sales +14%.
    | Comment!
  • Sep. 5, 2013, 7:04 AM
    • Nordion (NDZ): FQ3 EPS of $0.20 beats by $0.02.
    • Revenue of $71.7M (+7% Y/Y) beats by $10.58M. (PR)
    | Comment!
  • Jun. 5, 2013, 6:02 PM
    Nordion (NDZ) posts a mixed FQ2, missing on a per share basis but beating on revenue. Total sales rose by 12% Y/Y, but net profit fell 77% as the medical-technology company posted significantly higher selling and administrative expenses. Targeted-therapies revenue was up 6.1%, while sterilization-technologies sales jumped 36%. Sales in the medical-isotopes segment however, were roughly flat. Total costs and expenses grew 17%, as SG&A costs rose 58%.
    | Comment!
  • Mar. 7, 2013, 2:21 PM
    Health science firm Nordion (NDZ +0.6%) ticks higher today on an upgrade at RBC Capital to Sector Perform on the back of its better than expected FQ1 earnings report yesterday, with a price target of $8 a share. The company also announced it had initiated a review of strategic alternatives with a view to enhancing shareholder value and creating new opportunities. Read more on earnings here: Earnings Call Transcript.
    | 1 Comment
  • Mar. 5, 2013, 5:03 PM
    Nordion (NDZ): FQ1 EPS of $0.07 beats by $0.04. Revenue of $53.7M (+1% Y/Y) beats by $3.7M. (PR)
    | Comment!
  • Jan. 28, 2013, 7:03 AM
    Nordion (NDZ): Q4 EPS of $0.34 beats by $0.08. Revenue of $74.7M (+1% Y/Y) beats by $2M. (PR)
    | Comment!
  • Dec. 12, 2012, 6:36 PM
    Nordion (NDZ) postpones the release of its Q4 and FY12 financial results and conference call scheduled for December 18 and 19, respectively, saying it's initiated discussions to amend the terms of the company’s credit facility. The discussions are related to the potential impact of ongoing litigation and the treatment of certain non-cash items. Shares -5.4% AH.
    | Comment!
  • Sep. 6, 2012, 12:43 PM
    Canadian medical-technology company Nordion (NDZ +0.8%) gains after its FQ3 swung to a profit on fewer one-time expenses and higher sales. The quarter marks a reversal as sales have slipped in recent quarters, due in part to supply interruptions and the temporary shutdown of a reactor. In its targeted-therapies segment, revenue grew 15%, while gross margins widened to 54.7% from 52.7%.
    | Comment!
  • Jun. 6, 2012, 12:44 PM
    Nordion (NDZ -7.2%) slides after its FQ2 missed Street expectations across the board. Revenue slipped across all of the medical-science company's main business segments, as special items weighed on Y/Y results.
    | Comment!
Visit Seeking Alpha's
Company Description
Nordion Inc is a health science company that provides products used for the prevention, diagnosis and treatment of disease. The Company mainly provides targeted therapies, sterilization technologies and medical isotopes.
Sector: Healthcare
Country: Canada